PDCD1 and neoplasm: With the rise of the application of immune checkpoint inhibitor in tumor treatment, such as Programmed Cell death-1 (PD-1) inhibitors (Kitamura et al., 2020), there are many ongoing trials in HNSCC that focus on identifying new biomarkers (Gavrielatou et al., 2020).